Cationic macromolecules condense DNA into small nanoparticles and kind polyplex. The composition of the polyplex determines the endocytic course of, the intracellular routing and the destiny of the polyplex. Beforehand, oligochitosan-modified vectors with completely different protein moieties are used as gene supply vector and the varieties of protein moiety can affect the endosome escape capability and transfection effectivity. Among the many modified vectors, oligochitosan-modified bovine serum albumin (BSA) confirmed 90% transfection efficeincy in comparison with the modified zein and ovalbumin.
These knowledge inspired us to research the mechanism of internalization concerned within the superior transfection effectivity of modified BSA/ plasmid polyplex. The impact of particular endocytic inhibitors was studied in two adherent cell traces. The caveolae-mediated and lipid-mediated pathways play a big position within the polyplex internalization. Subsequent, a colocation of polyplex with lysosome was investigated within the presence of LysoTracker utilizing confocal microscopy.
As much as 70% of polyplex efficiently escaped the lysosome with out degradation. 4 non-adherent cell traces confirmed above than 60% transfection effectivity at an optimized vector/plasmid ratio. Furthermore, no important hemolytic impact was noticed as much as 500 μg/mL of cationic BSA, indicating no detectable cell membrane disruption. General, the hybrid biomacromolecule confirmed good intracellular supply and security in a mice mannequin.
Optimization of peptide-plasmid DNA vectors formulation for gene supply in most cancers remedy exploring design of experiments.
The sphere of gene remedy nonetheless attracts nice curiosity resulting from its potential therapeutic impact in the direction of probably the most lethal ailments, equivalent to most cancers. For most cancers gene remedy to be possible and viable in a scientific setting, the design and growth of an acceptable gene supply system is crucial. Peptide primarily based vectors, particularly, disclose to be promising for therapeutic gene launch. Following this, two completely different peptides, RALA and WRAP5, have been investigated primarily relating to their capability to kind complexes with a p53 encoding plasmid (pDNA) with appropriate properties for gene supply.
To deal with this problem, and after an preliminary screening research targeted on the dependence of pDNA complexation capability with the nitrogen to phosphate teams (N/P) ratio, a design of experiments (DoE) instrument has been employed. For every peptide/pDNA system, parameters equivalent to, the buffer pH and the N/P ratio have been thought of the DoE inputs and the vector dimension, zeta potential and pDNA complexation capability (CC) have been monitored as DoE outputs. The primary purpose was to search out the optimum experimental situations to attenuate particle sizes, in addition to, to maximise the optimistic floor fees of the formulated nanosystems and maximize the pDNA CC.
By means of the DoE methodology utilized, the optimum RALA/pDNA and WRAP5/pDNA formulations have been revealed and present attention-grabbing options associated to peptide construction and pDNA complexation capability. This work illustrates the nice utility of experimental design instruments in optimizing the formulation of peptide/pDNA vectors in a minimal variety of experiments offering related data for the event of extra appropriate and environment friendly gene supply methods. The brand new insights achieved on these carriers clearly instigate deeper analysis on gene remedy.
Novel Expression Vectors Based mostly on the pIGDM1 Plasmid.
Escherichia coli is likely one of the most generally used hosts for the manufacturing of heterologous proteins. Inside this host, the selection of cloning vector constitutes a key issue for a passable amplified expression of a goal gene. We aimed to develop novel, unpatented expression vectors that allow the steady upkeep and environment friendly overproduction of proteins in E. coli. A collection of expression vectors primarily based on the ColE1-like pIGDM1 plasmid have been constructed. The vectors named pIGDMCT7RS, pIGDM4RS and pIGDMKAN carry numerous antibiotic resistance genes: chloramphenicol, ampicillin or kanamycin, respectively. Two derivatives comprise the inducible T7 promoter whereas the third one bears the constitutive pms promoter from a scientific pressure of Klebsiella pneumoniae.
The pIGDM1-derivatives are appropriate with different ColE1-like plasmids generally utilized in molecular cloning. The pIGDMCT7RS and pIGDM4RS vectors comprise genes encoding AGA and AGG tRNAs, which complement the scarcity of those tRNAs, growing the effectivity of synthesis of heterologous proteins. In conclusion, pIGDMCT7RS, pIGDM4RS and pIGDMKAN vectors, with considerably improved options, together with compatibility with overwhelming majority of different plasmids, have been designed and constructed. They allow a high-level expression of a desired recombinant gene and due to this fact represent a possible, precious instrument for pharmaceutical corporations and analysis laboratories for their very own analysis or for the manufacturing of recombinant biopharmaceuticals.
Minimal plasmids play a necessary position in lots of intermediate steps in molecular biology. For instance, they can be utilized to assemble constructing blocks in artificial biology or be used as intermediate cloning plasmids that are perfect for PCR-based mutagenesis strategies. A small spine additionally opens up for added distinctive restriction enzyme cloning websites. Right here we describe the technology of pICOz, a 1185-bp absolutely useful high-copy cloning plasmid with an prolonged a number of cloning web site. We imagine that that is the smallest high-copy cloning vector ever described.
Single Plasmid-Based mostly, Upgradable, and Backward-Suitable Adenoviral Vector Programs.
Current adenoviral vector methods have two drawbacks. It’s labor-intensive and time-consuming to load a transgene in these methods, and transgene-harboring vectors are lifeless ends: they can’t be reused to assemble a vector carrying one other transgene or attaining new traits. To beat these shortcomings, single plasmid-based adenoviral vector methods have been constructed the place a singular PmeI web site was positioned on the place for insertion of the exogenous gene.
Saccharomyces cerevisiae Trehalose-phosphatase (TPS2) |
|||
| 1-CSB-RP165694Ye(c) | Cusabio |
|
|
|
Description: Recombinant Saccharomyces cerevisiae Trehalose-phosphatase(TPS2),partial expressed in E.coli |
|||
Mouse Protein Muc5ac (Muc5ac) |
|||
| 1-CSB-RP172294m(C) | Cusabio |
|
|
|
Description: Recombinant Mouse Protein Muc5ac(Muc5ac),partial expressed in E.coli |
|||
Human Histone deacetylase 7 (HDAC7) |
|||
| 1-CSB-RP178994h(C) | Cusabio |
|
|
|
Description: Recombinant Human Histone deacetylase 7(HDAC7),partial expressed in E.coli |
|||
Human Telomerase protein component 1 (TEP1) |
|||
| 1-CSB-RP180494h(c) | Cusabio |
|
|
|
Description: Recombinant Human Telomerase protein component 1(TEP1),partial expressed in E.coli |
|||
Human Collagen alpha-1 (XVII) chain (COL17A1) |
|||
| 1-CSB-RP180994h(c) | Cusabio |
|
|
|
Description: Recombinant Human Collagen alpha-1(XVII) chain(COL17A1),partial expressed in E.coli |
|||
Saccharomyces cerevisiae Neutral trehalase (NTH1) |
|||
| 1-CSB-RP181594Ye(c) | Cusabio |
|
|
|
Description: Recombinant Saccharomyces cerevisiae Neutral trehalase(NTH1),partial expressed in E.coli |
|||
Human Nuclear pore membrane glycoprotein 210 (NUP210) |
|||
| 1-CSB-EP016195HU(C) | Cusabio |
|
|
|
Description: Recombinant Human Nuclear pore membrane glycoprotein 210(NUP210),partial expressed in E.coli |
|||
anti- c-MYC antibody |
|||
| FNab01791 | FN Test | 100µg | EUR 702 |
|
Description: Antibody raised against c-MYC |
|||
Anti-c-Myc Antibody |
|||
| PA1555 | BosterBio | 100ug/vial | EUR 352.8 |
Anti-c-Myc Antibody |
|||
| PB9092 | BosterBio | 100ug/vial | EUR 400.8 |
Anti-c-MYC antibody |
|||
| PAab01791 | Lifescience Market | 100 ug | EUR 494.4 |
Anti-C-myc antibody |
|||
| STJ160092 | St John's Laboratory | 7 mL P | EUR 834 |
Anti-c-myc antibody |
|||
| STJ180021 | St John's Laboratory | 0.1 ml | EUR 282 |
Anti-c-Myc antibody |
|||
| STJ119460 | St John's Laboratory | 100 µl | EUR 332.4 |
|
Description: The protein encoded by this gene is a multifunctional, nuclear phosphoprotein that plays a role in cell cycle progression, apoptosis and cellular transformation. It functions as a transcription factor that regulates transcription of specific target genes. Mutations, overexpression, rearrangement and translocation of this gene have been associated with a variety of hematopoietic tumors, leukemias and lymphomas, including Burkitt lymphoma. There is evidence to show that alternative translation initiations from an upstream, in-frame non-AUG (CUG) and a downstream AUG start site result in the production of two isoforms with distinct N-termini. The synthesis of non-AUG initiated protein is suppressed in Burkitt's lymphomas, suggesting its importance in the normal function of this gene. |
|||
Anti-c-Myc antibody |
|||
| STJ97127 | St John's Laboratory | 200 µl | EUR 236.4 |
|
Description: Rabbit polyclonal to c-Myc. |
|||
Anti-c-Myc antibody |
|||
| STJ92355 | St John's Laboratory | 200 µl | EUR 236.4 |
|
Description: Rabbit polyclonal to c-Myc. |
|||
Anti-c-Myc antibody |
|||
| STJ92356 | St John's Laboratory | 200 µl | EUR 236.4 |
|
Description: c-Myc is a protein encoded by the MYC gene which is approximately 48,8 kDa. c-Myc is localised to the nucleus. It is involved in signalling by NOTCH1, CDK-mediated phosphorylation and removal of Cdc6 and ERK signalling. It functions as a transcription factor that regulates transcription of specific target genes. It plays a role in cell cycle progression, apoptosis and cellular transformation. c-Myc is expressed in the nervous system, intestine, blood, liver and bone marrow. Mutations in the MYC gene may result in Burkitt lymphoma. STJ92356 was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen. This polyclonal antibody detects endogenous levels of c-Myc protein. |
|||
Anti-c-Myc antibody |
|||
| STJ92357 | St John's Laboratory | 200 µl | EUR 236.4 |
|
Description: Rabbit polyclonal to c-Myc. |
|||
Anti-c-Myc antibody |
|||
| STJ92358 | St John's Laboratory | 200 µl | EUR 236.4 |
|
Description: Rabbit polyclonal to c-Myc. |
|||
Anti-c-Myc antibody |
|||
| STJ92359 | St John's Laboratory | 200 µl | EUR 236.4 |
|
Description: Rabbit polyclonal to c-Myc. |
|||
Anti-c-Myc antibody |
|||
| STJ97962 | St John's Laboratory | 100 µl | EUR 280.8 |
|
Description: Mouse monoclonal to c-Myc. |
|||
Rabbit Polyclonal antibody Anti-CRBN |
|||
| Anti-CRBN | ImmunoStep | 50 µg | EUR 418.8 |
Anti-c-Myc Monoclonal Antibody |
|||
| M00026-1 | BosterBio | 100ug | EUR 476.4 |
|
Description: Rabbit Monoclonal c-Myc Antibody. Validated in WB and tested in Human, Mouse, Rat. |
|||
c-Myc Epitope (Myc) Antibody |
|||
| 20-abx132269 | Abbexa |
|
|
c-Myc Epitope (Myc) Antibody |
|||
| 20-abx130438 | Abbexa |
|
|
Anti-Myc Antibody |
|||
| A00112 | BosterBio | 100ul | EUR 476.4 |
|
Description: Rabbit Polyclonal Myc Antibody. Validated in IHC and tested in Human, Mouse. |
|||
Anti-MYC antibody |
|||
| STJ111071 | St John's Laboratory | 100 µl | EUR 332.4 |
|
Description: The protein encoded by this gene is a multifunctional, nuclear phosphoprotein that plays a role in cell cycle progression, apoptosis and cellular transformation. It functions as a transcription factor that regulates transcription of specific target genes. Mutations, overexpression, rearrangement and translocation of this gene have been associated with a variety of hematopoietic tumors, leukemias and lymphomas, including Burkitt lymphoma. There is evidence to show that alternative translation initiations from an upstream, in-frame non-AUG (CUG) and a downstream AUG start site result in the production of two isoforms with distinct N-termini. The synthesis of non-AUG initiated protein is suppressed in Burkitt's lymphomas, suggesting its importance in the normal function of this gene. |
|||
Anti-MYC antibody |
|||
| STJ113115 | St John's Laboratory | 100 µl | EUR 332.4 |
|
Description: The protein encoded by this gene is a multifunctional, nuclear phosphoprotein that plays a role in cell cycle progression, apoptosis and cellular transformation. It functions as a transcription factor that regulates transcription of specific target genes. Mutations, overexpression, rearrangement and translocation of this gene have been associated with a variety of hematopoietic tumors, leukemias and lymphomas, including Burkitt lymphoma. There is evidence to show that alternative translation initiations from an upstream, in-frame non-AUG (CUG) and a downstream AUG start site result in the production of two isoforms with distinct N-termini. The synthesis of non-AUG initiated protein is suppressed in Burkitt's lymphomas, suggesting its importance in the normal function of this gene. |
|||
Anti-MYC antibody |
|||
| STJ113455 | St John's Laboratory | 50 µl | EUR 344.4 |
|
Description: The protein encoded by this gene is a multifunctional, nuclear phosphoprotein that plays a role in cell cycle progression, apoptosis and cellular transformation. It functions as a transcription factor that regulates transcription of specific target genes. Mutations, overexpression, rearrangement and translocation of this gene have been associated with a variety of hematopoietic tumors, leukemias and lymphomas, including Burkitt lymphoma. There is evidence to show that alternative translation initiations from an upstream, in-frame non-AUG (CUG) and a downstream AUG start site result in the production of two isoforms with distinct N-termini. The synthesis of non-AUG initiated protein is suppressed in Burkitt's lymphomas, suggesting its importance in the normal function of this gene. |
|||
Anti-MYC Antibody |
|||
| STJ500591 | St John's Laboratory | 100 µg | EUR 571.2 |
Anti-MYC Antibody |
|||
| STJ500592 | St John's Laboratory | 100 µg | EUR 571.2 |
Anti-myc antibody |
|||
| STJ140011 | St John's Laboratory | 150 µg | EUR 277.2 |
|
Description: Goat polyclonal antibody to myc epitope tag. c-Myc epitope tag is useful for the labelling and detection of proteins by immunoprecipitation, immunostaining and immunoblotting techniques. Because of its small size, it is unlikely to affect the tagged protein's biochemical properties. |
|||
anti-c-Myc |
|||
| YF-PA13293 | Abfrontier | 100 ul | EUR 483.6 |
|
Description: Rabbit polyclonal to c-Myc |
|||
c-Myc Antibody |
|||
| AF7674 | Affbiotech | 200ul | EUR 540 |
c-Myc Antibody |
|||
| AF6054 | Affbiotech | 200ul | EUR 420 |
c-Myc Antibody |
|||
| AF6055 | Affbiotech | 200ul | EUR 420 |
c-Myc Antibody |
|||
| AF0358 | Affbiotech | 200ul | EUR 420 |
C-myc antibody |
|||
| 70R-CG001 | Fitzgerald | 100 ul | EUR 457.2 |
|
Description: Affinity purified Goat polyclonal C-myc antibody |
|||
c-Myc antibody |
|||
| 70R-32862 | Fitzgerald | 100 ug | EUR 548.4 |
|
Description: Rabbit polyclonal c-Myc antibody |
|||
C-myc Antibody |
|||
| 48044-100ul | SAB | 100ul | EUR 399.6 |
C-myc Antibody |
|||
| 48044-50ul | SAB | 50ul | EUR 286.8 |
C-myc antibody |
|||
| 70R-10651 | Fitzgerald | 1 ml | EUR 516 |
|
Description: Affinity purified Chicken polyclonal C-myc antibody |
|||
C-myc antibody |
|||
| 70-CC18 | Fitzgerald | 100 ug | EUR 397.2 |
|
Description: Affinity purified Chicken polyclonal C-myc antibody |
|||
C-myc antibody |
|||
| 20R-CC001 | Fitzgerald | 200 ug | EUR 457.2 |
|
Description: Chicken polyclonal C-myc antibody |
|||
c Myc antibody |
|||
| 10R-8403 | Fitzgerald | 100 ul | EUR 471.6 |
|
Description: Mouse monoclonal c Myc antibody |
|||
C-myc antibody |
|||
| 10R-C101a | Fitzgerald | 100 ug | EUR 651.6 |
|
Description: Mouse monoclonal C-myc antibody |
|||
c-Myc Antibody |
|||
| R30632 | NSJ Bioreagents | 100 ug | EUR 419 |
c-Myc Antibody |
|||
| RQ4860 | NSJ Bioreagents | 100ul | EUR 419 |
c-Myc Antibody |
|||
| RQ4861 | NSJ Bioreagents | 100ul | EUR 419 |
c-Myc Antibody |
|||
| V7971-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
|
Description: It recognizes a transcription factor of 64-67kDa, identified as c-myc. Its epitope spans between aa 410-419 (EQKLISEEDL) which is a specific portion of an alpha helical region of human c-myc protein. This MAb shows no cross-reaction with v-myc. c-myc is involved in the control of cell proliferation and differentiation and is amplified and/or overexpressed in a variety of tumors. Over-expression of c-myc protein occurs frequently in luminal cells of prostate intraepithelial neoplasia as well as in most primary carcinomas and metastatic disease. |
|||
c-Myc Antibody |
|||
| V7971-20UG | NSJ Bioreagents | 20 ug | EUR 219 |
|
Description: It recognizes a transcription factor of 64-67kDa, identified as c-myc. Its epitope spans between aa 410-419 (EQKLISEEDL) which is a specific portion of an alpha helical region of human c-myc protein. This MAb shows no cross-reaction with v-myc. c-myc is involved in the control of cell proliferation and differentiation and is amplified and/or overexpressed in a variety of tumors. Over-expression of c-myc protein occurs frequently in luminal cells of prostate intraepithelial neoplasia as well as in most primary carcinomas and metastatic disease. |
|||
c-Myc Antibody |
|||
| V7971SAF-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
|
Description: It recognizes a transcription factor of 64-67kDa, identified as c-myc. Its epitope spans between aa 410-419 (EQKLISEEDL) which is a specific portion of an alpha helical region of human c-myc protein. This MAb shows no cross-reaction with v-myc. c-myc is involved in the control of cell proliferation and differentiation and is amplified and/or overexpressed in a variety of tumors. Over-expression of c-myc protein occurs frequently in luminal cells of prostate intraepithelial neoplasia as well as in most primary carcinomas and metastatic disease. |
|||
c-Myc Antibody |
|||
| V8412-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
|
Description: It recognizes a transcription factor of 64-67kDa, identified as c-myc. This MAb shows no cross-reaction with v-myc. c-myc is involved in the control of cell proliferation and differentiation and is amplified and/or overexpressed in a variety of tumors. Over-expression of c-myc protein occurs frequently in luminal cells of prostate intraepithelial neoplasia as well as in most primary carcinomas and metastatic disease. |
|||
c-Myc Antibody |
|||
| V8412-20UG | NSJ Bioreagents | 20 ug | EUR 219 |
|
Description: It recognizes a transcription factor of 64-67kDa, identified as c-myc. This MAb shows no cross-reaction with v-myc. c-myc is involved in the control of cell proliferation and differentiation and is amplified and/or overexpressed in a variety of tumors. Over-expression of c-myc protein occurs frequently in luminal cells of prostate intraepithelial neoplasia as well as in most primary carcinomas and metastatic disease. |
|||
c-Myc Antibody |
|||
| V8412SAF-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
|
Description: It recognizes a transcription factor of 64-67kDa, identified as c-myc. This MAb shows no cross-reaction with v-myc. c-myc is involved in the control of cell proliferation and differentiation and is amplified and/or overexpressed in a variety of tumors. Over-expression of c-myc protein occurs frequently in luminal cells of prostate intraepithelial neoplasia as well as in most primary carcinomas and metastatic disease. |
|||
c-Myc Antibody |
|||
| V8454-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
|
Description: It recognizes a transcription factor of 64-67kDa, identified as c-myc. Its epitope spans between aa 410-419 (EQKLISEEDL) which is a specific portion of an alpha helical region of human c-myc protein. This MAb shows no cross-reaction with v-myc. c-myc is involved in the control of cell proliferation and differentiation and is amplified and/or overexpressed in a variety of tumors. Over-expression of c-myc protein occurs frequently in luminal cells of prostate intraepithelial neoplasia as well as in most primary carcinomas and metastatic disease. |
|||
c-Myc Antibody |
|||
| V8454-20UG | NSJ Bioreagents | 20 ug | EUR 219 |
|
Description: It recognizes a transcription factor of 64-67kDa, identified as c-myc. Its epitope spans between aa 410-419 (EQKLISEEDL) which is a specific portion of an alpha helical region of human c-myc protein. This MAb shows no cross-reaction with v-myc. c-myc is involved in the control of cell proliferation and differentiation and is amplified and/or overexpressed in a variety of tumors. Over-expression of c-myc protein occurs frequently in luminal cells of prostate intraepithelial neoplasia as well as in most primary carcinomas and metastatic disease. |
|||
c-Myc Antibody |
|||
| V8454SAF-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
|
Description: It recognizes a transcription factor of 64-67kDa, identified as c-myc. Its epitope spans between aa 410-419 (EQKLISEEDL) which is a specific portion of an alpha helical region of human c-myc protein. This MAb shows no cross-reaction with v-myc. c-myc is involved in the control of cell proliferation and differentiation and is amplified and/or overexpressed in a variety of tumors. Over-expression of c-myc protein occurs frequently in luminal cells of prostate intraepithelial neoplasia as well as in most primary carcinomas and metastatic disease. |
|||
c-Myc Antibody |
|||
| RQ6663 | NSJ Bioreagents | 100ug | EUR 419 |
|
Description: MYC proto-oncogene, bHLH transcription factor is a protein that in humans is encoded by the MYC gene which is a member of the myc family of transcription factors. The protein contains basic helix-loop-helix (bHLH) structural motif. This gene is a proto-oncogene and encodes a nuclear phosphoprotein that plays a role in cell cycle progression, apoptosis and cellular transformation. The encoded protein forms a heterodimer with the related transcription factor MAX. This complex binds to the E box DNA consensus sequence and regulates the transcription of specific target genes. Amplification of this gene is frequently observed in numerous human cancers. Translocations involving this gene are associated with Burkitt lymphoma and multiple myeloma in human patients. There is evidence to show that translation initiates both from an upstream, in-frame non-AUG (CUG) and a downstream AUG start site, resulting in the production of two isoforms with distinct N-termini. |
|||
C-Myc Antibody |
|||
| 6767-100 | Biovision | each | EUR 379.2 |
c-Myc Antibody |
|||
| F47610-0.08ML | NSJ Bioreagents | 0.08 ml | EUR 165 |
c-Myc Antibody |
|||
| F47610-0.4ML | NSJ Bioreagents | 0.4 ml | EUR 379 |
c-Myc Antibody |
|||
| F52056-0.08ML | NSJ Bioreagents | 0.08 ml | EUR 165 |
c-Myc Antibody |
|||
| F52056-0.4ML | NSJ Bioreagents | 0.4 ml | EUR 389 |
c-Myc Antibody |
|||
| V7021-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
|
Description: Transcription factor that binds DNA in a non-specific manner, yet also specifically recognizes the core sequence 5'-CAC[GA]TG-3'. Activates the transcription of growth-related genes. [UniProt] |
|||
c-Myc Antibody |
|||
| V7021-20UG | NSJ Bioreagents | 20 ug | EUR 219 |
|
Description: Transcription factor that binds DNA in a non-specific manner, yet also specifically recognizes the core sequence 5'-CAC[GA]TG-3'. Activates the transcription of growth-related genes. [UniProt] |
|||
c-Myc Antibody |
|||
| V7021IHC-7ML | NSJ Bioreagents | 7 ml | EUR 499 |
|
Description: Transcription factor that binds DNA in a non-specific manner, yet also specifically recognizes the core sequence 5'-CAC[GA]TG-3'. Activates the transcription of growth-related genes. [UniProt] |
|||
c-Myc Antibody |
|||
| V7021SAF-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
|
Description: Transcription factor that binds DNA in a non-specific manner, yet also specifically recognizes the core sequence 5'-CAC[GA]TG-3'. Activates the transcription of growth-related genes. [UniProt] |
|||
c-Myc Antibody |
|||
| V2744-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
|
Description: It recognizes a transcription factor of 64-67kDa, identified as c-myc. Its epitope spans between aa 410-419 (EQKLISEEDL) which is a specific portion of an alpha helical region of human c-myc protein. This mAb shows no cross-reaction with v-myc. c-myc is involved in the control of cell proliferation and differentiation and is amplified and/or overexpressed in a variety of tumors. Over-expression of c-myc protein occurs frequently in luminal cells of prostate intraepithelial neoplasia as well as in most primary carcinomas and metastatic disease. |
|||
c-Myc Antibody |
|||
| V2744-20UG | NSJ Bioreagents | 20 ug | EUR 219 |
|
Description: It recognizes a transcription factor of 64-67kDa, identified as c-myc. Its epitope spans between aa 410-419 (EQKLISEEDL) which is a specific portion of an alpha helical region of human c-myc protein. This mAb shows no cross-reaction with v-myc. c-myc is involved in the control of cell proliferation and differentiation and is amplified and/or overexpressed in a variety of tumors. Over-expression of c-myc protein occurs frequently in luminal cells of prostate intraepithelial neoplasia as well as in most primary carcinomas and metastatic disease. |
|||
c-Myc Antibody |
|||
| V2744IHC-7ML | NSJ Bioreagents | 7 ml | EUR 499 |
|
Description: It recognizes a transcription factor of 64-67kDa, identified as c-myc. Its epitope spans between aa 410-419 (EQKLISEEDL) which is a specific portion of an alpha helical region of human c-myc protein. This mAb shows no cross-reaction with v-myc. c-myc is involved in the control of cell proliferation and differentiation and is amplified and/or overexpressed in a variety of tumors. Over-expression of c-myc protein occurs frequently in luminal cells of prostate intraepithelial neoplasia as well as in most primary carcinomas and metastatic disease. |
|||
c-Myc Antibody |
|||
| V2744SAF-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
|
Description: It recognizes a transcription factor of 64-67kDa, identified as c-myc. Its epitope spans between aa 410-419 (EQKLISEEDL) which is a specific portion of an alpha helical region of human c-myc protein. This mAb shows no cross-reaction with v-myc. c-myc is involved in the control of cell proliferation and differentiation and is amplified and/or overexpressed in a variety of tumors. Over-expression of c-myc protein occurs frequently in luminal cells of prostate intraepithelial neoplasia as well as in most primary carcinomas and metastatic disease. |
|||
c-Myc Antibody |
|||
| V2745-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
|
Description: Myc, or c-Myc, is involved in the control of cell proliferation and differentiation and is amplified and/or overexpressed in a variety of tumors. Over-expression of c-Myc protein occurs frequently in luminal cells of prostate intraepithelial neoplasia as well as in most primary carcinomas and metastatic disease. |
|||
c-Myc Antibody |
|||
| V2745-20UG | NSJ Bioreagents | 20 ug | EUR 219 |
|
Description: Myc, or c-Myc, is involved in the control of cell proliferation and differentiation and is amplified and/or overexpressed in a variety of tumors. Over-expression of c-Myc protein occurs frequently in luminal cells of prostate intraepithelial neoplasia as well as in most primary carcinomas and metastatic disease. |
|||
c-Myc Antibody |
|||
| V2745IHC-7ML | NSJ Bioreagents | 7 ml | EUR 499 |
|
Description: Myc, or c-Myc, is involved in the control of cell proliferation and differentiation and is amplified and/or overexpressed in a variety of tumors. Over-expression of c-Myc protein occurs frequently in luminal cells of prostate intraepithelial neoplasia as well as in most primary carcinomas and metastatic disease. |
|||
c-Myc Antibody |
|||
| V2745SAF-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
|
Description: Myc, or c-Myc, is involved in the control of cell proliferation and differentiation and is amplified and/or overexpressed in a variety of tumors. Over-expression of c-Myc protein occurs frequently in luminal cells of prostate intraepithelial neoplasia as well as in most primary carcinomas and metastatic disease. |
|||
c-Myc Antibody |
|||
| V2746-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
|
Description: It recognizes a transcription factor of 64-67kDa, identified as c-myc. This mAb shows no cross-reaction with v-myc. c-Myc is a transcription factor that binds DNA in a non-specific manner, yet also specifically recognizes the core sequence 5'-CAC[GA]TG-3'. Activates the transcription of growth-related genes. [UniProt] |
|||
c-Myc Antibody |
|||
| V2746-20UG | NSJ Bioreagents | 20 ug | EUR 219 |
|
Description: It recognizes a transcription factor of 64-67kDa, identified as c-myc. This mAb shows no cross-reaction with v-myc. c-Myc is a transcription factor that binds DNA in a non-specific manner, yet also specifically recognizes the core sequence 5'-CAC[GA]TG-3'. Activates the transcription of growth-related genes. [UniProt] |
|||
c-Myc Antibody |
|||
| V2746IHC-7ML | NSJ Bioreagents | 7 ml | EUR 499 |
|
Description: It recognizes a transcription factor of 64-67kDa, identified as c-myc. This mAb shows no cross-reaction with v-myc. c-Myc is a transcription factor that binds DNA in a non-specific manner, yet also specifically recognizes the core sequence 5'-CAC[GA]TG-3'. Activates the transcription of growth-related genes. [UniProt] |
|||
c-Myc Antibody |
|||
| V2746SAF-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
|
Description: It recognizes a transcription factor of 64-67kDa, identified as c-myc. This mAb shows no cross-reaction with v-myc. c-Myc is a transcription factor that binds DNA in a non-specific manner, yet also specifically recognizes the core sequence 5'-CAC[GA]TG-3'. Activates the transcription of growth-related genes. [UniProt] |
|||
c-Myc Antibody |
|||
| V3124-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
|
Description: The c-Myc protein is a transcription factor, which is encoded by the c-Myc gene on human chromosome 8q24. c-Myc is commonly activated in a variety of tumor cells and plays an important role in cellular proliferation, differentiation, apoptosis and cell cycle progression. The phosphorylation of c-Myc has been investigated and previous studies have suggested a functional association between phosphorylation at Thr58/Ser62 by glycogen synthase kinase 3, cyclin dependent kinase, ERK2 and C-Jun N terminal Kinase (JNK) in cell proliferation and cell cycle regulation. Studies also have shown that c-Myc is essential for tumor cell development in vasculogenesis and angiogenesis that distribute blood throughout the cells, and which brought extensive attention in the development of new therapeutic approach for cancer treatment. |
|||
c-Myc Antibody |
|||
| V3124-20UG | NSJ Bioreagents | 20 ug | EUR 219 |
|
Description: The c-Myc protein is a transcription factor, which is encoded by the c-Myc gene on human chromosome 8q24. c-Myc is commonly activated in a variety of tumor cells and plays an important role in cellular proliferation, differentiation, apoptosis and cell cycle progression. The phosphorylation of c-Myc has been investigated and previous studies have suggested a functional association between phosphorylation at Thr58/Ser62 by glycogen synthase kinase 3, cyclin dependent kinase, ERK2 and C-Jun N terminal Kinase (JNK) in cell proliferation and cell cycle regulation. Studies also have shown that c-Myc is essential for tumor cell development in vasculogenesis and angiogenesis that distribute blood throughout the cells, and which brought extensive attention in the development of new therapeutic approach for cancer treatment. |
|||
c-Myc Antibody |
|||
| V3124SAF-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
|
Description: The c-Myc protein is a transcription factor, which is encoded by the c-Myc gene on human chromosome 8q24. c-Myc is commonly activated in a variety of tumor cells and plays an important role in cellular proliferation, differentiation, apoptosis and cell cycle progression. The phosphorylation of c-Myc has been investigated and previous studies have suggested a functional association between phosphorylation at Thr58/Ser62 by glycogen synthase kinase 3, cyclin dependent kinase, ERK2 and C-Jun N terminal Kinase (JNK) in cell proliferation and cell cycle regulation. Studies also have shown that c-Myc is essential for tumor cell development in vasculogenesis and angiogenesis that distribute blood throughout the cells, and which brought extensive attention in the development of new therapeutic approach for cancer treatment. |
|||
c-Myc Antibody |
|||
| V3125-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
|
Description: The c-Myc protein is a transcription factor, which is encoded by the c-Myc gene on human chromosome 8q24. c-Myc is commonly activated in a variety of tumor cells and plays an important role in cellular proliferation, differentiation, apoptosis and cell cycle progression. The phosphorylation of c-Myc has been investigated and previous studies have suggested a functional association between phosphorylation at Thr58/Ser62 by glycogen synthase kinase 3, cyclin dependent kinase, ERK2 and C-Jun N terminal Kinase (JNK) in cell proliferation and cell cycle regulation. Studies also have shown that c-Myc is essential for tumor cell development in vasculogenesis and angiogenesis that distribute blood throughout the cells, and which brought extensive attention in the development of new therapeutic approach for cancer treatment. |
|||
c-Myc Antibody |
|||
| V3125-20UG | NSJ Bioreagents | 20 ug | EUR 219 |
|
Description: The c-Myc protein is a transcription factor, which is encoded by the c-Myc gene on human chromosome 8q24. c-Myc is commonly activated in a variety of tumor cells and plays an important role in cellular proliferation, differentiation, apoptosis and cell cycle progression. The phosphorylation of c-Myc has been investigated and previous studies have suggested a functional association between phosphorylation at Thr58/Ser62 by glycogen synthase kinase 3, cyclin dependent kinase, ERK2 and C-Jun N terminal Kinase (JNK) in cell proliferation and cell cycle regulation. Studies also have shown that c-Myc is essential for tumor cell development in vasculogenesis and angiogenesis that distribute blood throughout the cells, and which brought extensive attention in the development of new therapeutic approach for cancer treatment. |
|||
c-Myc Antibody |
|||
| V3125SAF-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
|
Description: The c-Myc protein is a transcription factor, which is encoded by the c-Myc gene on human chromosome 8q24. c-Myc is commonly activated in a variety of tumor cells and plays an important role in cellular proliferation, differentiation, apoptosis and cell cycle progression. The phosphorylation of c-Myc has been investigated and previous studies have suggested a functional association between phosphorylation at Thr58/Ser62 by glycogen synthase kinase 3, cyclin dependent kinase, ERK2 and C-Jun N terminal Kinase (JNK) in cell proliferation and cell cycle regulation. Studies also have shown that c-Myc is essential for tumor cell development in vasculogenesis and angiogenesis that distribute blood throughout the cells, and which brought extensive attention in the development of new therapeutic approach for cancer treatment. |
|||
c-Myc Antibody |
|||
| V3158-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
|
Description: The c-Myc protein is a transcription factor, which is encoded by the c-Myc gene on human chromosome 8q24. c-Myc is commonly activated in a variety of tumor cells and plays an important role in cellular proliferation, differentiation, apoptosis and cell cycle progression. The phosphorylation of c-Myc has been investigated and previous studies have suggested a functional association between phosphorylation at Thr58/Ser62 by glycogen synthase kinase 3, cyclin dependent kinase, ERK2 and C-Jun N terminal Kinase (JNK) in cell proliferation and cell cycle regulation. Studies also have shown that c-Myc is essential for tumor cell development in vasculogenesis and angiogenesis that distribute blood throughout the cells, and which brought extensive attention in the development of new therapeutic approach for cancer treatment. |
|||
c-Myc Antibody |
|||
| V3158-20UG | NSJ Bioreagents | 20 ug | EUR 219 |
|
Description: The c-Myc protein is a transcription factor, which is encoded by the c-Myc gene on human chromosome 8q24. c-Myc is commonly activated in a variety of tumor cells and plays an important role in cellular proliferation, differentiation, apoptosis and cell cycle progression. The phosphorylation of c-Myc has been investigated and previous studies have suggested a functional association between phosphorylation at Thr58/Ser62 by glycogen synthase kinase 3, cyclin dependent kinase, ERK2 and C-Jun N terminal Kinase (JNK) in cell proliferation and cell cycle regulation. Studies also have shown that c-Myc is essential for tumor cell development in vasculogenesis and angiogenesis that distribute blood throughout the cells, and which brought extensive attention in the development of new therapeutic approach for cancer treatment. |
|||
c-Myc Antibody |
|||
| V3158IHC-7ML | NSJ Bioreagents | 7 ml | EUR 499 |
|
Description: The c-Myc protein is a transcription factor, which is encoded by the c-Myc gene on human chromosome 8q24. c-Myc is commonly activated in a variety of tumor cells and plays an important role in cellular proliferation, differentiation, apoptosis and cell cycle progression. The phosphorylation of c-Myc has been investigated and previous studies have suggested a functional association between phosphorylation at Thr58/Ser62 by glycogen synthase kinase 3, cyclin dependent kinase, ERK2 and C-Jun N terminal Kinase (JNK) in cell proliferation and cell cycle regulation. Studies also have shown that c-Myc is essential for tumor cell development in vasculogenesis and angiogenesis that distribute blood throughout the cells, and which brought extensive attention in the development of new therapeutic approach for cancer treatment. |
|||
c-Myc Antibody |
|||
| V3158SAF-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
|
Description: The c-Myc protein is a transcription factor, which is encoded by the c-Myc gene on human chromosome 8q24. c-Myc is commonly activated in a variety of tumor cells and plays an important role in cellular proliferation, differentiation, apoptosis and cell cycle progression. The phosphorylation of c-Myc has been investigated and previous studies have suggested a functional association between phosphorylation at Thr58/Ser62 by glycogen synthase kinase 3, cyclin dependent kinase, ERK2 and C-Jun N terminal Kinase (JNK) in cell proliferation and cell cycle regulation. Studies also have shown that c-Myc is essential for tumor cell development in vasculogenesis and angiogenesis that distribute blood throughout the cells, and which brought extensive attention in the development of new therapeutic approach for cancer treatment. |
|||
C-Myc Antibody |
|||
| 3995-100 | Biovision | each | EUR 392.4 |
C-Myc Antibody |
|||
| 3995-30T | Biovision | each | EUR 175.2 |
Human V-Myc Myelocytomatosis Viral Oncogene Homolog (MYC) ELISA Kit |
|||
| DLR-MYC-Hu-48T | DL Develop | 48T | EUR 597.6 |
|
Description: A sandwich quantitative ELISA assay kit for detection of Human V-Myc Myelocytomatosis Viral Oncogene Homolog (MYC) in samples from tissue homogenates, cell lysates or other biological fluids. |
|||
Human V-Myc Myelocytomatosis Viral Oncogene Homolog (MYC) ELISA Kit |
|||
| DLR-MYC-Hu-96T | DL Develop | 96T | EUR 776.4 |
|
Description: A sandwich quantitative ELISA assay kit for detection of Human V-Myc Myelocytomatosis Viral Oncogene Homolog (MYC) in samples from tissue homogenates, cell lysates or other biological fluids. |
|||
Mouse V-Myc Myelocytomatosis Viral Oncogene Homolog (MYC) ELISA Kit |
|||
| DLR-MYC-Mu-48T | DL Develop | 48T | EUR 609.6 |
|
Description: A sandwich quantitative ELISA assay kit for detection of Mouse V-Myc Myelocytomatosis Viral Oncogene Homolog (MYC) in samples from tissue homogenates, cell lysates or other biological fluids. |
|||
Mouse V-Myc Myelocytomatosis Viral Oncogene Homolog (MYC) ELISA Kit |
|||
| DLR-MYC-Mu-96T | DL Develop | 96T | EUR 793.2 |
|
Description: A sandwich quantitative ELISA assay kit for detection of Mouse V-Myc Myelocytomatosis Viral Oncogene Homolog (MYC) in samples from tissue homogenates, cell lysates or other biological fluids. |
|||
Rat V-Myc Myelocytomatosis Viral Oncogene Homolog (MYC) ELISA Kit |
|||
| DLR-MYC-Ra-48T | DL Develop | 48T | EUR 633.6 |
|
Description: A sandwich quantitative ELISA assay kit for detection of Rat V-Myc Myelocytomatosis Viral Oncogene Homolog (MYC) in samples from serum, plasma, tissue homogenates, cell lysates or other biological fluids. |
|||
Rat V-Myc Myelocytomatosis Viral Oncogene Homolog (MYC) ELISA Kit |
|||
| DLR-MYC-Ra-96T | DL Develop | 96T | EUR 828 |
|
Description: A sandwich quantitative ELISA assay kit for detection of Rat V-Myc Myelocytomatosis Viral Oncogene Homolog (MYC) in samples from serum, plasma, tissue homogenates, cell lysates or other biological fluids. |
|||
Human V-Myc Myelocytomatosis Viral Oncogene Homolog (MYC) ELISA Kit |
|||
| RD-MYC-Hu-48Tests | Reddot Biotech | 48 Tests | EUR 600 |
Human V-Myc Myelocytomatosis Viral Oncogene Homolog (MYC) ELISA Kit |
|||
| RD-MYC-Hu-96Tests | Reddot Biotech | 96 Tests | EUR 830.4 |
Mouse V-Myc Myelocytomatosis Viral Oncogene Homolog (MYC) ELISA Kit |
|||
| RD-MYC-Mu-48Tests | Reddot Biotech | 48 Tests | EUR 613.2 |
Mouse V-Myc Myelocytomatosis Viral Oncogene Homolog (MYC) ELISA Kit |
|||
| RD-MYC-Mu-96Tests | Reddot Biotech | 96 Tests | EUR 850.8 |
Rat V-Myc Myelocytomatosis Viral Oncogene Homolog (MYC) ELISA Kit |
|||
| RD-MYC-Ra-48Tests | Reddot Biotech | 48 Tests | EUR 640.8 |
Rat V-Myc Myelocytomatosis Viral Oncogene Homolog (MYC) ELISA Kit |
|||
| RD-MYC-Ra-96Tests | Reddot Biotech | 96 Tests | EUR 890.4 |
Human V-Myc Myelocytomatosis Viral Oncogene Homolog (MYC) ELISA Kit |
|||
| RDR-MYC-Hu-48Tests | Reddot Biotech | 48 Tests | EUR 626.4 |
Human V-Myc Myelocytomatosis Viral Oncogene Homolog (MYC) ELISA Kit |
|||
| RDR-MYC-Hu-96Tests | Reddot Biotech | 96 Tests | EUR 868.8 |
Mouse V-Myc Myelocytomatosis Viral Oncogene Homolog (MYC) ELISA Kit |
|||
| RDR-MYC-Mu-48Tests | Reddot Biotech | 48 Tests | EUR 640.8 |
Mouse V-Myc Myelocytomatosis Viral Oncogene Homolog (MYC) ELISA Kit |
|||
| RDR-MYC-Mu-96Tests | Reddot Biotech | 96 Tests | EUR 890.4 |
Rat V-Myc Myelocytomatosis Viral Oncogene Homolog (MYC) ELISA Kit |
|||
| RDR-MYC-Ra-48Tests | Reddot Biotech | 48 Tests | EUR 669.6 |
Rat V-Myc Myelocytomatosis Viral Oncogene Homolog (MYC) ELISA Kit |
|||
| RDR-MYC-Ra-96Tests | Reddot Biotech | 96 Tests | EUR 931.2 |
Anti-c-Myc Antibody (monoclonal, 9E10) |
|||
| MA1028 | BosterBio | 100ug/vial | EUR 400.8 |
Anti-c-Myc Oncoprotein Monoclonal Antibody |
|||
| M00026 | BosterBio | 100ug/vial | EUR 476.4 |
|
Description: Mouse Monoclonal c-Myc Oncoprotein Antibody. Validated in IHC and tested in Human. |
|||
Anti-Phospho-c-Myc (S373) antibody |
|||
| STJ90227 | St John's Laboratory | 200 µl | EUR 236.4 |
|
Description: Rabbit polyclonal to Phospho-c-Myc (S373). |
|||
Anti-Phospho-c-Myc (T358) antibody |
|||
| STJ90228 | St John's Laboratory | 200 µl | EUR 236.4 |
|
Description: Rabbit polyclonal to Phospho-c-Myc (T358). |
|||
Anti-Phospho-c-Myc (T58) antibody |
|||
| STJ90229 | St John's Laboratory | 200 µl | EUR 236.4 |
|
Description: Rabbit polyclonal to Phospho-c-Myc (T58). |
|||
Anti-Phospho-c-Myc (S62) antibody |
|||
| STJ91021 | St John's Laboratory | 200 µl | EUR 236.4 |
|
Description: Rabbit polyclonal to Phospho-c-Myc (S62). |
|||
Anti-c-Myc Oncoprotein Antibody (MYC275) |
|||
| A1450-100 | Biovision | each | EUR 574.8 |
Anti-C-Myc Antibody | RMYC-145D |
|||
| RMYC-145D | Immunology Consultants Laboratory | 2.0 mL | EUR 1157 |
|
Description: Anti-C-Myc Antibody | RMYC-145D | Immunology Consultants Laboratory Host: Rabbit Format: Agarose Immobilized Product Type: Primary Antibody Antibody Clonality: Polyclonal |
|||
Anti-C-Myc Antibody | RMYC-45A |
|||
| RMYC-45A | Immunology Consultants Laboratory | 1.0 mg | EUR 1142 |
|
Description: Anti-C-Myc Antibody | RMYC-45A | Immunology Consultants Laboratory Host: Rabbit Format: Unconjugated AP Product Type: Primary Antibody Antibody Clonality: Polyclonal |
|||
Anti-C-Myc Antibody | RMYC-45F |
|||
| RMYC-45F | Immunology Consultants Laboratory | 1.0 mg | EUR 1157 |
|
Description: Anti-C-Myc Antibody | RMYC-45F | Immunology Consultants Laboratory Host: Rabbit Format: FITC Conjugated Product Type: Primary Antibody Antibody Clonality: Polyclonal |
|||
Anti-C-Myc Antibody | RMYC-45P |
|||
| RMYC-45P | Immunology Consultants Laboratory | 1.0 mg | EUR 1173 |
|
Description: Anti-C-Myc Antibody | RMYC-45P | Immunology Consultants Laboratory Host: Rabbit Format: HRP Conjugated Product Type: Primary Antibody Antibody Clonality: Polyclonal |
|||
Anti-C-Myc Antibody | CMYC-45A |
|||
| CMYC-45A | Immunology Consultants Laboratory | 1.0 mg | EUR 1142 |
|
Description: Anti-C-Myc Antibody | CMYC-45A | Immunology Consultants Laboratory Host: Chicken Format: Unconjugated AP Product Type: Primary Antibody Antibody Clonality: Polyclonal |
|||
Anti-C-Myc Antibody | CMYC-45B |
|||
| CMYC-45B | Immunology Consultants Laboratory | 1.0 mg | EUR 1157 |
|
Description: Anti-C-Myc Antibody | CMYC-45B | Immunology Consultants Laboratory Host: Chicken Format: Biotin Conjugated Product Type: Primary Antibody Antibody Clonality: Polyclonal |
|||
Anti-C-Myc Antibody | CMYC-45F |
|||
| CMYC-45F | Immunology Consultants Laboratory | 1.0 mg | EUR 1157 |
|
Description: Anti-C-Myc Antibody | CMYC-45F | Immunology Consultants Laboratory Host: Chicken Format: FITC Conjugated Product Type: Primary Antibody Antibody Clonality: Polyclonal |
|||
Anti-C-Myc Antibody | CMYC-45P |
|||
| CMYC-45P | Immunology Consultants Laboratory | 1.0 mg | EUR 1173 |
|
Description: Anti-C-Myc Antibody | CMYC-45P | Immunology Consultants Laboratory Host: Chicken Format: HRP Conjugated Product Type: Primary Antibody Antibody Clonality: Polyclonal |
|||
Anti-C-Myc Antibody | GMYC-45A |
|||
| GMYC-45A | Immunology Consultants Laboratory | 0.1 mg | EUR 1142 |
|
Description: Anti-C-Myc Antibody | GMYC-45A | Immunology Consultants Laboratory Host: Goat Format: Unconjugated AP Product Type: Primary Antibody Antibody Clonality: Polyclonal |
|||
pcDNA3.0-TO-Myc-RAR |
|||
| PVTB00439-2a | Lifescience Market | 2 ug | EUR 427.2 |
pCDNA4- To- Myc- HisB |
|||
| PVT10694 | Lifescience Market | 2 ug | EUR 361.2 |
anti- MYC tag antibody |
|||
| FNab05456 | FN Test | 100µg | EUR 658.5 |
|
Description: Antibody raised against MYC tag |
|||
anti- MYC-tag antibody |
|||
| FNab05462 | FN Test | 100µg | EUR 606.3 |
|
Description: Antibody raised against MYC-tag |
|||
Anti-MYC-tag antibody |
|||
| PAab05462 | Lifescience Market | 100 ug | EUR 426 |
Anti-MYC Antibody (Biotin) |
|||
| STJ500593 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-MYC Antibody (FITC) |
|||
| STJ500594 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-MYC Antibody (Biotin) |
|||
| STJ500595 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-MYC Antibody (FITC) |
|||
| STJ500596 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-Myc-Tag antibody |
|||
| STJ96904 | St John's Laboratory | 200 µl | EUR 236.4 |
|
Description: Mouse monoclonal to Myc-Tag. |
|||
Anti-Myc-Tag antibody |
|||
| STJ96926 | St John's Laboratory | 200 µl | EUR 236.4 |
|
Description: Mouse monoclonal to Myc-Tag. |
|||
Anti-Myc-Tag antibody |
|||
| STJ96929 | St John's Laboratory | 200 µl | EUR 236.4 |
|
Description: Mouse monoclonal to Myc-Tag. |
|||
Anti-Myc-Tag antibody |
|||
| STJ97044 | St John's Laboratory | 200 µl | EUR 236.4 |
|
Description: Mouse monoclonal to Myc-Tag. |
|||
Anti-Myc-Tag antibody |
|||
| STJ97078 | St John's Laboratory | 200 µl | EUR 236.4 |
|
Description: Rabbit polyclonal to Myc-Tag. |
|||
c-Myc Oncoprotein; Clone 9E10.3 (Concentrate) |
|||
| RA0226-C.1 | ScyTek Laboratories | 0.1 ml | EUR 150 |
c-Myc Oncoprotein; Clone 9E10.3 (Concentrate) |
|||
| RA0226-C.5 | ScyTek Laboratories | 0.5 ml | EUR 360 |
c-Myc Oncoprotein; Clone MYC909 (Concentrate) |
|||
| RA0227-C.1 | ScyTek Laboratories | 0.1 ml | EUR 150 |
c-Myc Oncoprotein; Clone MYC909 (Concentrate) |
|||
| RA0227-C.5 | ScyTek Laboratories | 0.5 ml | EUR 360 |
The polymerase chain response (PCR) amplified transgene could possibly be cloned into PmeI-linearized beginning plasmids utilizing one step of Gibson meeting to generate goal adenoviral plasmids, which have been then prepared for virus rescue. This process was termed restriction meeting.